KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Non-Current Liabilities (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $9.8 billion as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 24.17% to $9.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.8 billion through Dec 2025, up 24.17% year-over-year, with the annual reading at $9.8 billion for FY2025, 24.17% up from the prior year.
  • Total Non-Current Liabilities hit $9.8 billion in Q4 2025 for Royalty Pharma, up from $9.2 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $9.8 billion in Q4 2025 to a low of $6.3 billion in Q3 2023.
  • Historically, Total Non-Current Liabilities has averaged $7.6 billion across 5 years, with a median of $7.3 billion in 2022.
  • Biggest five-year swings in Total Non-Current Liabilities: decreased 13.62% in 2023 and later increased 25.15% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $7.3 billion in 2021, then grew by 0.25% to $7.3 billion in 2022, then dropped by 13.57% to $6.3 billion in 2023, then increased by 25.15% to $7.9 billion in 2024, then grew by 24.17% to $9.8 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for RPRX at $9.8 billion in Q4 2025, $9.2 billion in Q3 2025, and $8.7 billion in Q2 2025.